He Hao, Li Changxiang, Lu Xiangyu, Li Yanqin, Li Xuan, Sun Xiaoqian, Tang Binghua, Wu Yan, Li Chun
School of Life Science, Beijing University of Chinese Medicine, Beijing 100029, China.
College of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Evid Based Complement Alternat Med. 2021 Dec 31;2021:5779307. doi: 10.1155/2021/5779307. eCollection 2021.
. Qishen granules (QSG) are a frequently prescribed formula with cardioprotective properties prescribed to HF for many years. RNA-seq profiling revealed that regulation on cardiac mitochondrial energy metabolism is the main therapeutic effect. However, the underlying mechanism is still unknown. In this study, we explored the effects of QSG on regulating mitochondrial energy metabolism and oxidative stress through the PGC-1/NRF1/TFAM signaling pathway. RNA-seq technology revealed that QSG significantly changed the differential gene expression of mitochondrial dysfunction in myocardial ischemic tissue. The mechanism was verified through the left anterior descending artery- (LAD-) induced HF rat model and oxygen glucose deprivation/recovery- (OGD/R-) established H9C2 induction model both and . Echocardiography and HE staining showed that QSG could effectively improve the cardiac function of rats with myocardial infarction in functionality and structure. Furthermore, transcriptomics revealed QSG could significantly regulate mitochondrial dysfunction-related proteins at the transcriptome level. The results of electron microscopy and immunofluorescence proved that the mitochondrial morphology, mitochondrial membrane structural integrity, and myocardial oxidative stress damage can be effectively improved after QSG treatment. Mechanism studies showed that QSG increased the expression level of mitochondrial biogenesis factor PGC-1/NRF1/TFAM protein and regulated the balance of mitochondrial fusion/fission protein expression. QSG could regulate mitochondrial dysfunction in ischemia heart tissue to protect cardiac function and structure in HF rats. The likely mechanism is the adjustment of PGC-1/NRF1/TFAM pathway to alleviate oxidative stress in myocardial cells. Therefore, PGC-1 may be a potential therapeutic target for improving mitochondrial dysfunction in HF.
芪参颗粒(QSG)是一种常用于治疗心力衰竭(HF)且具有心脏保护作用的方剂,多年来一直用于HF的治疗。RNA测序分析表明,对心脏线粒体能量代谢的调节是其主要治疗作用。然而,其潜在机制仍不清楚。在本研究中,我们探讨了芪参颗粒通过PGC-1/NRF1/TFAM信号通路对线粒体能量代谢和氧化应激的调节作用。RNA测序技术表明,芪参颗粒显著改变了心肌缺血组织中线粒体功能障碍的差异基因表达。通过左冠状动脉前降支(LAD)诱导的HF大鼠模型和氧糖剥夺/复氧(OGD/R)建立的H9C2诱导模型对该机制进行了验证。超声心动图和苏木精-伊红(HE)染色显示,芪参颗粒可有效改善心肌梗死大鼠心脏功能的功能和结构。此外,转录组学显示芪参颗粒可在转录组水平显著调节线粒体功能障碍相关蛋白。电子显微镜和免疫荧光结果证明,芪参颗粒治疗后可有效改善线粒体形态、线粒体膜结构完整性和心肌氧化应激损伤。机制研究表明,芪参颗粒增加了线粒体生物发生因子PGC-1/NRF1/TFAM蛋白的表达水平,并调节了线粒体融合/分裂蛋白表达的平衡。芪参颗粒可调节缺血性心脏组织中的线粒体功能障碍,保护HF大鼠的心脏功能和结构。其可能机制是通过调节PGC-1/NRF1/TFAM通路减轻心肌细胞的氧化应激。因此,PGC-1可能是改善HF中线粒体功能障碍的潜在治疗靶点。